Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | RARB | P10826 | 11/20 | 0.56 |
| ▸ | RARA | P10276 | 10/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.53 |
| ▸ | RARG | P13631 | 11/20 | 0.50 |
| ▸ | RXRA | P19793 | 6/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8459938 | 0.84 | GABRG2 (0.54) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL9184735 | 0.82 | RARB (0.55) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL2788640 | 0.81 | CYP3A4 (0.70) | CYP3A4RARBRARACYP26A1RARG | |
| SCHEMBL8461756 | 0.81 | RARB (0.53) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL8462120 | 0.81 | CYP3A4 (0.51) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL9188355 | 0.81 | CYP3A4 (0.56) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL9183745 | 0.81 | RARB (0.74) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL9186798 | 0.81 | CYP3A4 (0.56) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL9185577 | 0.80 | RARG (0.53) | CYP3A4RARBRARAABCB1ABCC1 | |
| SCHEMBL18775432 | 0.80 | RARB (0.73) | CYP3A4RARBRARACYP26A1RARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999048529-A1 | RETINOID-GLITAZONE COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-30 | — | — | WO | disclosed |
| EP-0808159-A1 | USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0382077-B1 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| US-5338749-A | Treating rheumatic or arthritic disorders | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
| EP-0382077-A2 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |